An evaluation of nebulized prostacyclin in patients with primary and secondary pulmonary hypertension

Abstract

Nebulized prostacyclin appears to be more effective at reducing pulmonary artery pressure in patients with pulmonary hypertension when compared to intravenous prostacyclin and inhaled nitric oxide. This could have important clinical implications for the management of patients with pulmonary hypertensions.